Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin
Autore:
Kakolyris, S; Kourousis, C; Koukourakis, M; Androulakis, N; Vamvakas, L; Agelaki, S; Hatzidaki, D; Samonis, G; Tsiftsis, D; Georgoulias, V;
Indirizzi:
Univ Heraklion, Gen Hosp, Dept Med Oncol, Sch Med, Heraklion 71110, Crete,Greece Univ Heraklion Heraklion Crete Greece 71110 Heraklion 71110, Crete,Greece
Titolo Testata:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
fascicolo: 6, volume: 22, anno: 1999,
pagine: 568 - 572
SICI:
0277-3732(199912)22:6<568:FTOMBC>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II TRIAL; COMBINATION CHEMOTHERAPY; NAVELBINE; DOXORUBICIN; VINBLASTINE;
Keywords:
mitoxantrone; vinorelbine; carboplatin; metastatic breast cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Kakolyris, S Univ Heraklion, Gen Hosp, Dept Med Oncol, Sch Med, Heraklion 71110, Crete,Greece Univ Heraklion Heraklion Crete Greece 71110 10, Crete,Greece
Citazione:
S. Kakolyris et al., "First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin", AM J CL ONC, 22(6), 1999, pp. 568-572

Abstract

A phase II trial was conducted with mitoxantrone (12 mg/m(2), day 1), vinorelbine (30 mg/m(2), day 1), and carboplatin (250 mg/m2, day 2) every 21 days. Fifty eligible women who had not received prior chemotherapy for metastatic boast cancer (MBC) entered the study. Objective responses were observed in 28 patients (56%; 95% confidence interval: 42.4-69.74%), with 4 complete (8%) and 24 partial responses (48%). Stable disease was observed in 12 patients (24%) and disease progression in 10 (20%). Responses were documented in all involved sites. The median duration of response was 6 months and the median time to tumor progression 8 months. The median survival was 26 months and the estimated 2-year survival was 52%. Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes. Grade 3/4 anemia and thrombacytopenia was observed in 7 (14%) and 11 (22%) patients, respectively. Other toxicities included grade 2/3 nausea and vomiting in 26 patients (52%) and grade 1/2 alopecia in 38 (76%). Grade 1/2 neurosensory toxicity occurred in four patients (8%). In conclusion, this three-drug regimenis effective and well tolerated for the treatment of MBC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 20:19:28